Bienvenue chez nous!
Logo Ex Libris

Methods of Cancer Diagnosis, Therapy and Prognosis

  • Livre Relié
  • 727 Nombre de pages
This book covers all aspects of breast cancer, including diagnosis, treatments, and prognosis. It highlights the efficacy of vario... Lire la suite
CHF 469.00
Habituellement expédié sous 4 à 5 jours ouvrés.

Description

This book covers all aspects of breast cancer, including diagnosis, treatments, and prognosis. It highlights the efficacy of various anticancer drugs and their side-effects are pointed out, as well as the necessity of age-dependent breast cancer strategies.

The enormity of the global healthcare costs vical. One-fifth of all cancers worldwide as a result of cancer infliction cannot be are caused by a chronic infection, for overemphasized. There are more than 100 example, human papilloma virus (HPV) types of cancers; any part of the body can causes cervical cancer and hepatitis B be affected. More than 11 million people virus (HBV) causes liver cancer. Tobacco are diagnosed with cancer every year, and use is the most common preventable cause it is estimated that there will be 16 mil- of cancer in the world. Approximately, lion new cases per year by the year 2020. 168,000 cancer deaths are expected to be In 2005, 7. 6 million people died of can- caused by tobacco use. Approximately, cer, that is, 13% of the 58 million deaths 40% of cancer could be prevented, mainly worldwide. It is estimated that 9 million by not using tobacco, having a healthy people will die from cancer worldwide in diet, being physically active, preventing 2015 and 11. 4 million will die in 2030. infections that may cause cancer, reduc- More than 70% of all cancer deaths occur ing exposure to sunlight, and avoidance of in low and middle income countries. excessive alcohol consumption and stress Five major cancer causing overall mor- (anger). A third of cancers could be cured talities per year worldwide are (WHO): if detected early and treated adequately. It is well established that scientific 1. Lung: 1.

Texte du rabat

Cancer killed 6.7 million people around the world in 2002, and this figure is expected to rise to 10.1 million in 2020. Approximately, 189,510 new cases of breast cancer were reported in 2007 in the United States, and 40,910 died in the same year. Both principles and practice of breast oncology are presented in this volume. Node negative breast cancer, sebaceous cancer of the breast, phyllodes tumors of the breast, metaplastic breast cancer, invasive breast cancer, and multifocal and multicenter breast cancers are discussed. Breast cancer detection is explained using high throughput, MicroRNA expression, computer-aided detection, in vivo imaging of angiogenesis, contrast-enhanced digital mammography, sentinel node biopsy, and cytology in nipple-aspirated fluid. Validation of breast cancer biomarkers using tissue microarrays, epigenetic markers in blood, and HER-2 and EGFR expression. Role of BRCA1 and BRCA2 genes and their protein products in breast cancer is included. Also are discussed breast cancer recurrence, detection of circulating cancer cells, and prediction of metastasis. Breast conserving therapy versus Mastectomy is compared. Multimodality treatment, palliative treatment, and neoadjuvant therapy are discussed in detail. TOC:1.BREAST CANCER: COMPUTER-AIDED DETECTION, 2.SEBACEOUS CARCINOMA OF THE BREAST: CLINICOPATHOLOGIC FEATURES, 3. BREAST CANCER: DETECTION BY IN VIVO IMAGING OF ANGIOGENESIS, 4. BREAST AND PROSTATE BIOPSIES: USE OF OPTIMIZED HIGH-THROUGHPUT MicroRNA EXPRESSION FOR DIAGNOSIS (METHODOLOGY), 5. FAMILIAL BREAST CANCER: DETECTION OF PREVALENT HIGH-RISK EPITHELIAL LESIONS, 6. DIFFERENTIATION BETWEEN BENIGN AND MALIGNANT PAPILLARY LESIONS OF THE BREAST: EXCISIONAL BIOPSY OR STEREOTACTIC VACUUM-ASSISTED BIOPSY (METHODOLOGY), 7. MULTICENTRIC BREAST CANCER: SENTINEL NODE BIOPSY AS A DIAGNOSTIC TOOL, 8. BREAST CANCER RECURRENCE: ROLE OF SERUM TUMOR MARKERS CEA AND CA 15-3 (METHODOLOGY), 9. BREAST CANCER PATIENTS BEFORE, DURING OR AFTER TREATMENT: CIRCULATING TUMOR CELLS IN PERIPHERAL BLOOD DETECTED BY MULTIGENE REAL- TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION, 10. BREAST CANCER PATIENTS: DIAGNOSTIC EPIGENETIC MARKERS IN BLOOD, 11. BREAST CANCER PATIENTS: DETECTION OF CIRCULATING CANCER CELL RELATED mRNA MARKERS BY MEMBRANE ARRAY METHOD, 12. PREDICTION OF METASTASIS AND RECURRENCE OF BREAST CARCINOMA: DETECTION OF SURVIVIN- EXPRESSING CIRCULATING CANCER CELLS, 13. NODE-NEGATIVE BREAST CANCER: PREDICTIVE AND PROGNOSTIC VALUE OF PERIPHERAL BLOOD CYTOKERATIN-19 mRNA-POSITIVE CELLS, 14. BREAST AND COLON CARCINOMAS: DETECTION WITH PLASMA CRIPTO-1, 15. BREAST CANCER RISK IN WOMEN WITH ABNORMAL CYTOLOGY IN NIPPLE ASPIRATE FLUID, 16. TISSUE MICROARRAYS: CONSTRUCTION AND UTILIZATION FOR BIOMARKER STUDIES, 17. SYSTEMATIC VALIDATION OF BREAST CANCER BIOMARKERS USING TISSUE MICROARRAYS: FROM CONSTRUCTION TO IMAGE ANALYSIS, 18. PHYLLODES TUMORS OF THE BREAST: ROLE OF IMMUNOHISTOCHEMISTRY IN DIAGNOSIS, 19. PHYLLODES TUMOR OF THE BREAST: PROGNOSIS ASSESSMENT USING IMMUNOHISTOCHEMISTRY, 20. METAPLASTIC BREAST CARCINOMA: DETECTION USING HISTOLOGY AND IMMUNOHISTOCHEMISTRY, 21. INVASIVE BREAST CANCER: OVEREXPRESSION OF HER-2 DETERMINED BY IMMUNOHISTOCHEMISTRY AND MULTIPLEX LIGAND-DEPENDENT PROBE AMPLIFICATION, 22. OPERABLE BREAST CANCER: NEOADJUVANT TREATMENT (METHODOLOGY), 23. CHEMOTHERAPY FOR BREAST CANCER, 24. LOCALLY ADVANCED BREAST CANCER: ROLE OF CHEMOTHERAPY IN IMPROVING PROGNOSIS, 25. THE RELEVANCE OF DOSE-INTENSITY FOR ADJUVANT TREATMENT OF BREAST CANCER, 26. ADVANCED BREAST CANCER: TREATMENT WITH DOCETAXEL/EPIRUBICIN, 27. SYSTEMIC THERAPY FOR BREAST CANCER: USING TOXICITY DATA TO INFORM DECISIONS, 28. CHEMOTHERAPY FOR METASTATIC BREAST CANCER: PATIENTS WHO RECEIVED ADJUVANT ANTHRACYCLINES (AN OVERVIEW), 29. ESTROGEN RECEPTOR-NEGATIVE AND HER-2/neu- POSITIVE LOCALLY ADVANCED BREAST CARCINOMA: THERAPY WITH PACLIAXEL AND GRANULOCYTE-COLONY STIMULATING FACTOR, 30. BREAST CANCER: SIDE EFFECTS OF TAMOXIFEN AND ANASTROZOLE, 31. BREAST CANCER: EXPRESSION OF HER-2 AND EPIDERMAL GROWTH FACTOR RECEPTOR AS CLINI

Contenu

1. BREAST CANCER: COMPUTER-AIDED DETECTION Bin Zheng INTRODUCTION DEVELOPMENT OF COMPUTER-AIDED DETECTION SCHEMES EVALUATION OF COMPUTER-AIDED DETECTION SCHEME PERFORMANCE APPLICATION OF COMPUTER-AIDED DETECTION SCHEMES TO CLINICAL ENVIRONMENT NEW DEVELOPMENTS IN COMPUTER-AIDED DETECTION RESEARCH REFERENCES 2. SEBACEOUS CARCINOMA OF THE BREAST: CLINICOPATHOLOGIC FEATURES INTRODUCTION METHODS CLINICAL FEATURES PATHOLOGIC FINDINGS DIFFERENTIAL DIAGNOSIS PROGNOSIS AND TREATMENT REFRENCES 3. BREAST CANCER: DETECTION BY IN VIVO IMAGING OF ANGIOGENESIS Tore Bach-Gansmo and Derek Tobin INTRODUCTION ANGIOGENESIS INTEGRINS SCINTIMAMMOGRAPHY TECHNETIUM-LABELED NC100692 INITIAL CLINICAL EXPERIENCE 99mTc-NC100692 IN BREAST CANCER IMPROVEMENTS IN GAMMA CAMERA TECHNOLOGY SUPPLEMENTARY CLINICAL STUDY FUTURE INTEGRIN SCINTIGRAPHY REFERENCES 4. BREAST AND PROSTATE BIOPSIES: USE OF OPTIMIZED HIGH-THROUGHPUT MicroRNA EXPRESSION FOR DIAGNOSIS (METHODOLOGY) Michael D. Mattie and Robert C. Getts INTRODUCTION METHODOLOGY FOR HIGH-THROUGHPUT microRNA PROFILING Purification of microRNA AMPLIFICATION OF LOW MOLECULAR WEIGHT RNA LABELING OF microRNA REFERENCES 5. FAMILIAL BREAST CANCER: DETECTION OF PREVALENT HIGH-RISK EPITHELIAL LESIONS Peter Bult and Nicoline Hoogerbrugge INTRODUCTION MATERIALS METHODS CLASSIFICATION OF PREMALIGNANT LESIONS REFERENCES 6. DIFFERENTIATION BETWEEN BENIGN AND MALIGNANT PAPILLARY LESIONS OF THE BREAST: EXCISIONAL BIOPSY OR STEREOTACTIC VACUUM-ASSISTED BIOPSY (METHODOLOGY) Alice P.Y. Tang, Gary M.K. Tse, and Wynnie W.M. Lam INTRODUCTION RADIOLOGICAL APPEARANCE OF PAPPILARY LESIONS OF THE BREAST PATHOLOGICAL FINDINGS ASSOCIATION OF PAPPILARY LESIONS WITH DUCTAL CARCINOMA FINE NEEDLE ASPIRATION CORE NEEDLE BIOPSY CURRENT ROLE OF EXCISIONAL BIOPSY DIFFICULTY IN PATHOLOGICAL DIFFERENTIATION BETWEEN MALIGNANT AND BENIGN LESIONS AFTER NEEDLE BIOPSY VACCUM-ASSISTED BIOPSY TECHNIQUE OF STEREOTACTIC VACCUM-ASSISTED BIOPSY TECHNIQUE OF ULTRASOUND-GUIDED VACCUM-ASSISTED BIOPSY ADVANTAGES OF DIRECTIONAL VACCUM-ASSISTED DEVICE COMPLICATIONS OF VACCUM ASSISTED BIOPSY CURRENT EXPERIENCE OF VACCUM-ASSISTED BIOPSY AND PERCUTANEOUS CORE BIOPSY IN THE MANAGEMENT OF PAPPILARY LESIONS IS EXCISION BIOPSY NEEDED IN ASSESSING PAPPILARY LESIONS OF THE BREAST ATYPICAL PAPILLOMA/ PAPILLARY LESION WITH ATYPICAL DUCTAL HYPERPLASIA AT VACCUM-ASSISTED BIOPSY BENIGN PAPILLOMA AT VACCUM-ASSISTED BIOPSY REFERENCES 7. MULTICENTRIC BREAST CANCER: SENTINEL NODE BIOPSY AS A DIAGNOSTIC TOOL Michael Knauer, Peter Konstantiniuk, Anton Haid, Etienne Wenzl, Roswitha Köberle-Wührer, Michaela Riegler-Keil, Sabine Pöstlberger, Roland Reitsamer, and Peter Schrenk INTRODUCTION TECHNIQUE OF SENTINEL NODE BIOPSY IN MULTICENTRIC BREAST CANCER Technique of Lymphatic Mapping Histologic Evaluation of Sentinel Nodes Surgical Procedures RESULTS OF THE AUSTRIAN SENTINEL NODE STUDY GROUP Patients and Data Follow-up DISCUSSION Clinical Advantage of Sentinel Node Biopsy in Multicentric Breast Cancer Quality Control of Sentinel Node Biopsy Procedure REFERENCES 8. BREAST CANCER RECURRENCE: ROLE OF SERUM TUMOR MARKERS CEA AND CA 15-3 (METHODOLOGY) Franco Lumachi, Stefano M.M. Basso, and Umberto Basso INTRODUCTION SERUM TUMOR MARKERS AND BREAST CANCER CARCINOEMBRYONIC ANTIGEN CANCER ANTIGEN 15-3 PREDICTION OF RISK OF RECURRENCE AND LOCOREGIONAL RELAPSE MONITORING THE RESPONSE TO THERAPY OF

Détails sur le produit

Titre: Methods of Cancer Diagnosis, Therapy and Prognosis
Sous-titre: Breast Carcinoma
Éditeur:
Code EAN: 9781402083686
ISBN: 1402083688
Format: Livre Relié
Genre: Médecine
nombre de pages: 727
Poids: 1928g
Taille: H269mm x B202mm x T36mm
Parution: 01.12.2008
Année: 2008